<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01354691</url>
  </required_header>
  <id_info>
    <org_study_id>CR100101/CO15570</org_study_id>
    <nct_id>NCT01354691</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease</brief_title>
  <official_title>A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avraham Pharmaceuticals Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avraham Pharmaceuticals Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For many, Alzheimer's disease is the number one medical issue facing our aging society. It is
      a late onset neurodegenerative disease, frequently under diagnosed, that impairs memory and
      cognitive performance. There are no known treatments that can either prevent or reverse its
      progression. Consequently, there still remains a need to evaluate treatments which can better
      stabilize the symptoms of this disease. These symptoms frequently include decreased
      functional capacity and negative psychological attributes (e,g, depression, anxiety) in
      association with the memory and cognition deficits. This current study is being done to
      assess an investigational compound that has been designed to not only improved the cognitive
      status of affected patients but to also better manage all symptoms. Hence, the ultimate goal
      is to provide patients with an improved quality of life by slowing the progression of this
      neurodegenerative disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II, proof of concept study to evaluate the safety and efficacy of the
      investigational compound ladostigil versus placebo in mild to moderate Alzheimer's disease
      patients. The randomized, double-blind, placebo-controlled phase of the trial will be 26
      weeks in duration and will involve two cohorts (i.e. one arm receiving ladostigil and one arm
      receiving placebo). After the initial 26 week period, all participating subjects will receive
      26 weeks of treatment with ladostigil (i.e. the open label phase). A total of five
      territories will be participating in this trial. These include Austria, Croatia, Germany,
      Serbia and Spain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale</measure>
    <time_frame>26 weeks</time_frame>
    <description>11 item, unmodified ADAS-Cog (total possible score of 70)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety Evaluation</measure>
    <time_frame>6,15 26, 39 and 52 week assessment of safety and tolerability</time_frame>
    <description>Number and severity of adverse events across trial period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>6, 15, 26, 39 and 52 weeks</time_frame>
    <description>Assessment of behavioral and psychological symptoms of disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cornell Scale for Depression in Dementia (CSDD)</measure>
    <time_frame>6, 15, 26, 39 and 52 weeks</time_frame>
    <description>Assessment of depressive status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>6, 15, 26, 39 and 52 weeks</time_frame>
    <description>Assessment of functional activity status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Mental State Examination (MMSE)</measure>
    <time_frame>6, 15, 26, 39 and 52 weeks</time_frame>
    <description>Secondary assessment of cognitive status utilizing common metric</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADAS-Cog: Alzheimer's Disease Assessment Scale - Cognitive Subscale</measure>
    <time_frame>6, 15, 39 and 52 weeks</time_frame>
    <description>11 item, unmodified ADAS-Cog (total possible score of 70)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Dementia</condition>
  <condition>Memory Loss</condition>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>ladostigil hemitartrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ladostigil hemitartrate</intervention_name>
    <description>Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.</description>
    <arm_group_label>ladostigil hemitartrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AD diagnosis according to NINCDS-ADRDA criteria

          -  Mild to moderate AD according to MMSE 14-24 inclusive

          -  MRI or CT assessment within 6 months before baseline, corroborating the clinical
             diagnosis and excluding other potential causes of dementia especially cerebrovascular
             lesions

          -  Absence of major depressive disease according to CSDD of less than or equal to 18

          -  Modified Hachinski Ischemic Scale equal to or below 4

          -  Education for eight or more years

          -  Previous decline in cognition for more than six months as documented in patient
             medical records

          -  A caregiver available and living in the same household or interacting with the patient
             daily and available if necessary to assure administration of investigational product

          -  Patients living at home or nursing home setting without continuous nursing care

          -  General health status acceptable for participation in a 12-month clinical trial and
             ability to swallow oral medication

          -  No history of treatment with rivastigmine

          -  For patients with either donepezil or galantamine anti-cholinesterase inhibitor
             treatment prescribed, stopped treatment four weeks prior to screening

          -  For patients with memantine treatment prescribed, stopped treatment four weeks prior
             to screening

        Exclusion Criteria:

          -  Other primary degenerative dementias (e.g. dementia with Lewy bodies, fronto-temporal
             dementia, Huntington's disease, Jacob-Creutzfeldt disease)

          -  Other neurodegenerative conditions (Parkinson's disease. amyotrophic lateral
             sclerosis, etc)

          -  Other central nervous system diseases (severe head trauma, tumors, subdural hematoma,
             etc)

          -  A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar
             disorder

          -  Seizure disorders

          -  Other infectious, metabolic or systemic diseases affecting central nervous system
             (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency, serum
             electrolytes out of normal range, juvenile onset diabetes mellitus, etc)

          -  Clinically significant, advanced or unstable disease that may interfere with primary
             or secondary variable evaluations

          -  Other unstable, chronic or clinically significant medical conditions involving major
             organs like kidney, liver, lungs and heart/vasculature

          -  Hospitalization or change of chronic concomitant medications one month prior to
             screening or during screening period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reinhold Schmidt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MEDIZINISCHE UNIVERSITAT GRAZ</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Univeritat Graz, Universitatsklinik fur Neurologie, Auenbruggerplatz 22</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatordination Horn, HamerlingstraBe 15</name>
      <address>
        <city>Horn</city>
        <zip>3580</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus der Stadt Linz, KrankenhausstraBe 9</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Privatordination, Lainzerstrasse 20</name>
      <address>
        <city>Wein</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Pula, Negrijeva 6</name>
      <address>
        <city>Pula</city>
        <zip>52100</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Zabok, Bracak 8</name>
      <address>
        <city>Zabok</city>
        <zip>49210</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zagreb, Kispaticeva 12</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Dubrava, Avenija Gojka Suska 6</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinic Neuron, Salata 12</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Hospital Vrapce, Bolnicka cesta 32</name>
      <address>
        <city>Zagreb</city>
        <zip>10090</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg GmbH, Hoheluftaussee 18</name>
      <address>
        <city>Hanburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Schwerin GmbH, FriedrichstraBe 1</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Nordwest, Lange StraBe 23-25</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Serbia, Dr. Subotica 6</name>
      <address>
        <city>Beograd</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military Medical Academy, Crnotravska 17</name>
      <address>
        <city>Beograd</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAE Oroitu Centro Atencion Especializada C/Jata, 9</name>
      <address>
        <city>Algorta (Vizcaya)</city>
        <zip>48993</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Geroinnova Barcelona, Calle Mandoni n 17</name>
      <address>
        <city>Barcelona</city>
        <zip>08004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacio ACE, Institut Catala de Neurosciencies Aplicadas, C/Margues de Sentmenat 35-37</name>
      <address>
        <city>Barcelona</city>
        <zip>08014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institud d' Assistencia Sanitaria de Girona, Edifici La Republica - C/Dr. Castany, s/n</name>
      <address>
        <city>SALT (Girona)</city>
        <zip>17190</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Croatia</country>
    <country>Germany</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2011</study_first_submitted>
  <study_first_submitted_qc>May 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2011</study_first_posted>
  <last_update_submitted>July 22, 2013</last_update_submitted>
  <last_update_submitted_qc>July 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Memory Loss</keyword>
  <keyword>Cognitive Impairment</keyword>
  <keyword>Brain Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Delirium, Dementia, Amnestic, Cognitive Disorders</keyword>
  <keyword>Mental Disorders</keyword>
  <keyword>Depression</keyword>
  <keyword>Anxiety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
    <mesh_term>Memory Disorders</mesh_term>
    <mesh_term>Amnesia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

